Have to see value where it is miss priced. And what fundamentals are layering together.
Collaboration with Siemens, and multiple different cancer targets on the horizon.
Market that to US investors.
The Australian market, priced it speculatively at a previous high of 200m mc. Why ? Because the prize of $$ volumes of NPs in a med tech growth space.
Do you want that barbaric biopsy that could actually spread the cancer ? or do you want non invasive ? non radioactive ?
Consolidation in effect today, page-10
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
